Arterial Vascular Engineering stock's January debut on "The Gray Sheet" Index coincided with a solid 8-1/2 point (13.1%) run-up during the month to 73-1/2. Investor enthusiasm for the issue, roused by the Dec. 23 approval of the company's Micro Stent II and GFX coronary stent systems, was heightened further by Wall Street predictions of "explosive" stent market growth in 1998.
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
A surgeon at Ochsner Health in New Orleans was able to successfully remove a rare and dangerous tumor from a patient’s spine using cutting-edge technology that would have otherwise made the procedure too risky.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.
